How do you treat patients with newly diagnosed CLL in the era of new agents? In this commentary, Dr. Flinn discusses emerging frontline combination regimens for the treatment of CLL.
Are you aware of some of the latest clinical data in CLL? In this commentary, I will discuss 3 key studies on venetoclax, acalabrutinib, and lisocabtagene maraleucel in CLL that were presented at ASCO 2019.
Jeff P. Sharman, MD; Nichole Fisher, RN, BSN; and Emily Bucholtz, RPh, review patient cases and supporting clinical data to provide guidance on optimizing care for chronic lymphocytic leukemia.
Download these slides to review the most recent clinical data on new agents in both frontline and relapsed/refractory CLL.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.